WALTHAM, Mass., June 26, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has enrolled the first patient in its corneal wound repair pivotal study in patients having undergone photorefractive keratectomy (“PRK”) surgery. Barbara Wirostko MD, Chief Medical Officer of EyeGate, said, “There is a significant need for an…
WALTHAM, Mass., Aug. 01, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced positive data from its Phase 1b/2a trial assessing its lead product candidate, iontophoretic EGP-437, in the treatment of post-operative ocular…
WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first three patients have been randomized in its study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to reduce…
WALTHAM, Mass., April 13, 2018 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, announced today the pricing of a public offering of an aggregate of 35,156,250 shares of common stock (or common stock equivalents) and warrants…
WALTHAM, Mass., June 27, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase shares…
WALTHAM, MA, December 31, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has entered into a definitive agreement with certain institutional investors to purchase 500,000 shares of the Company’s common stock at a purchase…
WALTHAM, Mass., April 17, 2018 — EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, announced today the completion of its previously announced public offering of 14,730,000 shares of the Company’s common stock, 6,536.4 shares of Series…
WALTHAM, Mass., June 30, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the completion of its previously announced offering of the Company’s common stock and of Series A Convertible…
WALTHAM, MA, January 3, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced the completion of its previously announced registered direct offering priced at-the-market under Nasdaq Rules of 500,000 shares of the Company’s common stock at a…
WALTHAM, Mass., June 01, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced interim data from its Phase 1b/2a trial evaluating its lead product candidate, iontophoretic EGP-437, in the treatment of…